# A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

> **NCT03052608** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Pfizer** · enrollment: 296 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** Lorlatinib
- **DRUG:** Crizotinib

## Key facts

- **NCT ID:** NCT03052608
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-04-27
- **Primary completion:** 2020-03-20
- **Final completion:** 2028-12-31
- **Target enrollment:** 296 (ACTUAL)
- **Last updated:** 2025-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03052608

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03052608, "A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03052608. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*